Karolinska Development’s portfolio company Umecrine Cognition raises additional funding for the clinical development of golexanolone
STOCKHOLM, SWEDEN – November 17, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the portfolio company Umecrine Cognition has conducted a capital raise, implemented as a convertible loan with attached share options,
for the continued development of its drug candidate golexanolone. Karolinska Development participates as part of an investor consortium in the financing round that brings Umecrine Cognition a total of SEK 30.4 million.
The investor consortium consists of Karolinska Development, AB Ility, Ribbskottet AB, and other current long-term shareholders in Umecrine Cognition. The dilutive effect of the transaction will result in a negative earnings effect of SEK 12 million for Karolinska Development in the fourth quarter of 2023.
The funding will be used to finance the ongoing clinical Phase 2 trial of golexanolone in primary biliary cholangitis as well as working capital.
“The additional funding will enable Umecrine Cognition to continue its important ongoing clinical trial to evaluate the safety profile, pharmacokinetics, and preliminary efficacy of golexanolone in the targeted patient population. Our portfolio company has recently presented strong preclinical data that strengthens our faith in the drug candidate, and we look forward to following the continued development,” says Viktor Drvota, CEO of Karolinska Development.
Karolinska Development's ownership in Umecrine Cognition currently amounts to 73%. Upon full exercise of the share options attached to the convertible loan, as well as two earlier convertible loans with similar terms, Karolinska Developments' shareholding will decrease to 62%, if full conversion takes place, including that the options are redeemed.
For further information, please contact:
Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: email@example.com
Johan Dighed, General Counsel and Deputy CEO, Karolinska Development AB
Phone: +46 70 207 48 26, e-mail: firstname.lastname@example.org
TO THE EDITORS
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.
Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.
Karolinska Development has a portfolio of eleven companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.
The company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.
For more information, please visit www.karolinskadevelopment.com
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
BBS-Bioactive Bone Substitutes Plc: Managers' Transactions - Pekka Jalovaara7.12.2023 18:00:00 CET | Press release
BBS-Bioactive Bone Substitutes Plc, Company announcement, Management transactions, 7 December 2023 at 7.00 p.m. (EET) BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions – Pekka Jalovaara ____________________________________________ Person subject to the notification requirement Name: Jalovaara Pekka Position: Member of the Board/Deputy member Issuer: BBS Bioactive Bone Substitutes Oyj LEI: 743700BYSBP0PCR6N767 Notification type: INITIAL NOTIFICATION Reference number: 743700BYSBP0PCR6N767_20231207173757_8 ____________________________________________ Transaction date: 2023-12-04 Venue not applicable Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT ISIN: FI4000260583 Nature of the transaction: DISPOSAL Transaction details (1): Volume: 133,850 Unit price: 0.005 EUR Aggregated transactions (1): Volume: 133,850 Volume weighted average price: 0.005 EUR ____________________________________________ Transaction date: 2023-12-05 Venue not applicable Instrument
Intervest Offices & Warehouses NV: Press release – Persbericht – Communiqué de presse: publication of a transparency notification7.12.2023 18:00:00 CET | Press release
Dear Madam, Sir, Please find hereunder the links to Intervest Offices & Warehouses’ latest press release regarding the publication of a transparency notification. Geachte mevrouw, meneer, Gelieve hierbij de links te vinden naar het recente persbericht van Intervest Offices & Warehouses betreffende de openbaarmaking over transparantiekennisgeving. Chère Madame, Cher Monsieur, Veuillez trouver ci-dessous les liens vers le récent communiqué de presse d’Intervest Offices & Warehouses concernant la communication relative à une notification de transparence. Attachments ENG_transparency notification_20231201_FINNL_transparency notification_20231201_FINFR_transparency notification_20231201_FIN
75% Load Factor, 42% increase in passenger numbers and demand picking up7.12.2023 17:50:00 CET | Press release
75% Load Factor, 42% increase in passenger numbers and demand picking up PLAY airlines carried 107,236 passengers in November, which is a 42% increase from November 2022 when PLAY carried 75,396 passengers. The load factor in November 2023 was 74.5%, down from 79% last year. This decline in load factor is a direct result of the seismic activity in the Reykjanes Peninsula and resulting global news coverage of a possible volcanic eruption that could disrupt aviation. This situation impacted last-minute bookings in the month. PLAY had an on-time performance of 88.9% in November 2023. Despite the decline in load factor in November we continued to see year-on-year growth in our unit revenue (RASK), even with a 54% growth in available seat kilometers (ASK).Average ancillary revenue continues to rise for PLAY, being 30% higher in November 2023 compared to November 2022, and the trend is looking strong for the coming months. Of all passengers flying with PLAY in November 2023, 26.2% were depar
Innofactor Plc: Share Repurchase 7.12.20237.12.2023 17:30:00 CET | Press release
Innofactor Plc Announcement 7.12.2023Innofactor Plc: Share Repurchase 7.12.2023In the Helsinki Stock ExchangeTrade date 7.12.2023Bourse trade BuyShare IFA1VAmount 4,500SharesAverage price/ share 1.1494EURTotal cost 5,172.30EURInnofactor Plc now holds a total of 575 629 sharesincluding the shares repurchased on 7.12.2023On behalf of Innofactor PlcNordea Bank OyjJanne Sarvikivi Sami HuttunenAdditional information:Sami Ensio, CEOInnofactor PlcTel. +358 50 584 email@example.com Attachment Innofactor_7.12_trades
Coloplast A/S - Skift af revisor7.12.2023 17:29:40 CET | pressemeddelelse
I dag, den 7. december 2023, har Coloplast A/S afholdt ordinær generalforsamling, hvor EY Godkendt Revisionspartnerselskab blev valgt som Coloplast A/S’ revisor i overensstemmelse med forslaget fra bestyrelsen. For yderligere information, kontakt venligst Investorer og analytikere Anders Lonning-Skovgaard Koncerndirektør, CFO Tlf. 4911 1111 Aleksandra Dimovska Senior Director, Investor Relations Tlf. 4911 1800 / 4911 2458 E-mail: firstname.lastname@example.org Kristine Husted Munk Senior Manager, Investor Relations Tlf. 4911 1800 / 4911 3266 E-mail: email@example.com Presse og medier Peter Mønster Sr. Media Relations Manager Tlf. 4911 2623 Email: firstname.lastname@example.org Adresse Coloplast A/S Holtedam 1 3050 Humlebæk Danmark CVR Nr. 69749917 Hjemmeside www.coloplast.com Denne selskabsmeddelelse foreligger på dansk og engelsk. I tvivlstilfælde er den engelske version gældende. Coloplast blev grundlagt på passion, ambition og engagement. Vi opstod på grundlag af en sygeplejerskes ønske om at hjælpe